BriaCell Therapeutics Corp. Banner Image

BriaCell Therapeutics Corp. has reached its limit for free report views

Work for BriaCell Therapeutics Corp.? Upgrade Your Profile and unlock all your annual reports.

BriaCell Therapeutics Corp.

  • Ticker BCTX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
BriaCell Therapeutics Corp. Logo Image
  • 1-10 Employees
  • Based in Berkeley, California
BriaCell (TSXV: BCT) (OTCQB: BCTXF) is a clinical stage immuno-oncology focused biotechnology company developing the first off the shelf personalized immunotherapy for cancer. The company is conducting a Phase IIa clinical trial for its lead product candidate, Bria-IMT™, in advanced breast cancer along with the co-development of BriaDX™, its companion diagnostic. Additionally, there isMore an FDA approved combination study of Bria-IMT™ with pembrolizumab or ipilimumab for patients with advanced breast cancer previously treated with Bria-IMT™. Moreover, BriaCell is developing Bria-OTS™, the first “off the shelf” personalized treatment for advanced stage Breast Cancer. BriaCell's small molecule program consists of novel, selective protein kinase C delta inhibitors which have shown activity in pre-clinical models of several cancers and fibrotic diseases.
BriaCell Therapeutics Corp.

Most Recent Annual Report

BriaCell Therapeutics Corp. MOST RECENT 2019 Annual Report

Report Locked. BriaCell Therapeutics Corp. has reached its limit for free report views.